Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 217

1.

Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote.

Gorry PR, Dunfee RL, Mefford ME, Kunstman K, Morgan T, Moore JP, Mascola JR, Agopian K, Holm GH, Mehle A, Taylor J, Farzan M, Wang H, Ellery P, Willey SJ, Clapham PR, Wolinsky SM, Crowe SM, Gabuzda D.

Virology. 2007 May 25;362(1):163-78. Epub 2007 Jan 18.

2.

Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain.

Gray L, Roche M, Churchill MJ, Sterjovski J, Ellett A, Poumbourios P, Sherieff S, Wang B, Saksena N, Purcell DF, Wesselingh S, Cunningham AL, Brew BJ, Gabuzda D, Gorry PR.

J Virol. 2009 Jun;83(11):5430-41. doi: 10.1128/JVI.02648-08. Epub 2009 Mar 25. Erratum in: J Virol. 2009 Aug;83(15):7794. Sheffief, Shameem [corrected to Sherieff, Shameem].

3.

Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages.

Cashin K, Roche M, Sterjovski J, Ellett A, Gray LR, Cunningham AL, Ramsland PA, Churchill MJ, Gorry PR.

J Virol. 2011 Oct;85(20):10699-709. doi: 10.1128/JVI.05510-11. Epub 2011 Aug 10.

4.

Linkages between HIV-1 specificity for CCR5 or CXCR4 and in vitro usage of alternative coreceptors during progressive HIV-1 subtype C infection.

Cashin K, Jakobsen MR, Sterjovski J, Roche M, Ellett A, Flynn JK, Borm K, Gouillou M, Churchill MJ, Gorry PR.

Retrovirology. 2013 Sep 16;10:98. doi: 10.1186/1742-4690-10-98.

5.

V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.

Laakso MM, Lee FH, Haggarty B, Agrawal C, Nolan KM, Biscone M, Romano J, Jordan AP, Leslie GJ, Meissner EG, Su L, Hoxie JA, Doms RW.

PLoS Pathog. 2007 Aug 24;3(8):e117.

8.

[Biological characteristics of HIV-1 isolates circulating in China are linked to its env V3 loop sequence variability].

Hei FX, Hong KX, Song YH, Tang HL, Peng H, Xu JQ, Xing H, Shao YM.

Zhonghua Yi Xue Za Zhi. 2004 Dec 2;84(23):1968-72. Chinese.

PMID:
15730807
9.

Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage.

Verrier F, Borman AM, Brand D, Girard M.

AIDS Res Hum Retroviruses. 1999 May 20;15(8):731-43.

PMID:
10357469
10.

Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation.

Shi Y, Brandin E, Vincic E, Jansson M, Blaxhult A, Gyllensten K, Moberg L, Broström C, Fenyö EM, Albert J.

J Gen Virol. 2005 Dec;86(Pt 12):3385-96.

PMID:
16298986
11.

Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage.

Svicher V, Alteri C, Artese A, Zhang JM, Costa G, Mercurio F, D'Arrigo R, Alcaro S, Palù G, Clementi M, Zazzi M, Andreoni M, Antinori A, Lazzarin A, Ceccherini-Silberstein F, Perno CF; OSCAR study group.

Antivir Ther. 2011;16(7):1035-45. doi: 10.3851/IMP1862.

PMID:
22024519
12.

Distinct molecular pathways to X4 tropism for a V3-truncated human immunodeficiency virus type 1 lead to differential coreceptor interactions and sensitivity to a CXCR4 antagonist.

Del Prete GQ, Leslie GJ, Haggarty B, Jordan AP, Romano J, Hoxie JA.

J Virol. 2010 Sep;84(17):8777-89. doi: 10.1128/JVI.00333-10. Epub 2010 Jun 23.

13.

HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro.

Moncunill G, Armand-Ugón M, Pauls E, Clotet B, Esté JA.

AIDS. 2008 Jan 2;22(1):23-31.

PMID:
18090388
15.

Selected amino acid changes in HIV-1 subtype-C gp41 are associated with specific gp120(V3) signatures in the regulation of co-receptor usage.

Dimonte S, Babakir-Mina M, Mercurio F, Di Pinto D, Ceccherini-Silberstein F, Svicher V, Perno CF.

Virus Res. 2012 Sep;168(1-2):73-83. doi: 10.1016/j.virusres.2012.06.019. Epub 2012 Jun 23.

PMID:
22732432
18.

Genotypic coreceptor analysis.

Sierra S, Kaiser R, Thielen A, Lengauer T.

Eur J Med Res. 2007 Oct 15;12(9):453-62. Review.

PMID:
17933727
19.

Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists.

Lin G, Bertolotti-Ciarlet A, Haggarty B, Romano J, Nolan KM, Leslie GJ, Jordan AP, Huang CC, Kwong PD, Doms RW, Hoxie JA.

J Virol. 2007 Sep;81(18):9956-66. Epub 2007 Jul 3.

20.
Items per page

Supplemental Content

Write to the Help Desk